NZ

Novozymes A/SCSE Novozymes Stock Report

Last reporting period 31 Dec, 2023

Updated —

Last price

Market cap $B

10.808

Large

Exchange

XCSE - Nasdaq Copenhagen A/S

NZYM B.CO Stock Analysis

NZ

Uncovered

Novozymes A/S is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

59/100

Moderate score

Market cap $B

10.808

Dividend yield

Shares outstanding

227.26 B

Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. The firm operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. The company develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.

View Section: Eyestock Rating